

January 23, 2017

The Manager - Listing  
**National Stock Exchange of India Ltd.**  
Exchange plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E),  
Mumbai 400051

The Manager - Listing  
**BSE Limited**  
Corporate Relationship Dept., 1<sup>st</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai 400001

Dear Sir(s),

**Sub: Meeting of the Board of Directors of the Company to be held on Thursday, February 2, 2017**

**Ref: Scrip Code – BSE: 506820, NSE: ASTRAZEN**

This is to inform you that a meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on **Thursday, February 2, 2017** *inter alia*, to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2016.

We would also like to inform you that the 'Trading Window' was closed for all Designated Persons on **December 16, 2016** and continues to be closed upto **February 4, 2017 (both days inclusive)** in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.

Please take the same on record.

Thanking you,

Yours faithfully  
For AstraZeneca Pharma India Limited



Rajesh Marwaha  
Chief Financial Officer & Director